The treatment effects of SGLT2 inhibitors were assessed across 14 subgroups, which included LVEF, history of diabetes, age, sex, race, geographical region, KCCQ total symptom score, body mass index, estimated glomerular filtration rate (eGFR), history of atrial fibrillation or flutter, New York Heart Association (NYHA) functional class, hospitalization for HF within 12 months, N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentration, baseline use of mineralocorticoid receptor antagonists (MRAs), and baseline use of angiotensin receptor neprilysin inhibitors (ARNIs). This evidence concerns the gene SLC5A2 and diabetes mellitus.